Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 3, 2014, Pages 573-581

  Zhou, Nannan ^a   Nowicka Sans, Beata ^a   McAuliffe, Brian ^a   Ray, Neelanjana ^a   Eggers, Betsy ^a   Fang, Hua ^a   Fan, Li ^a   Healy, Matthew ^a   Langley, David R ^a   Hwang, Carey ^a   Lataillade, Max ^a   Hanna, George J ^a   Krystal, Mark ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antiretroviral; Envelope; Glycoprotein; Resistance; Tropism

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BMS-626529; BMS-663068; GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; ORGANOPHOSPHATE; PIPERAZINE DERIVATIVE; PRODRUG; TRIAZOLE DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; DNA SEQUENCE; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR GENETICS; REVERSE GENETICS; VIROLOGY;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; ORGANOPHOSPHATES; PIPERAZINES; PRODRUGS; REVERSE GENETICS; SEQUENCE ANALYSIS, DNA; TRIAZOLES;

EID: 84894062192     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt412     Document Type: Article

References (24)

1. Kadow J, Wang HG, Lin PF. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug development. Curr Opin Investig Drugs 2006; 7: 721-6.
2. Guo Q,Ho HT, Dicker I et al. Biochemicalandgeneticcharacterizations ofa novel human immunodeficiency virus type 1 inhibitor that blocks gp120- CD4 interactions. J Virol 2003; 77: 10528-36.
3. Madani N, Perdigoto AL, SrinivasanKet al. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J Virol 2004; 78: 3742-52.
4. Hanna GJ, Lalezari J,Hellinger JA et al. Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, inHIV-1-infected subjects. Antimicrob Agents Chemother 2011; 55: 722-8.
5. Nowicka-Sans B, Gong YF, McAuliffe B et al. In vitroantiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob Agents Chemother 2012; 56: 3498-507.
6. Nettles R, Schurmann D, Zhu L et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis 2012; 206: 1002-11.
7. Ray N, Hwang C, Healy MD et al. Prediction of virologic response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068. J Acquir Immune Defic Syndr 2013; 64: 7-15.
8. Lou S, Moquist PN, Schaus SE. Asymmetric allylboration of acyl imines catalyzed by chiral diols. J Am Chem Soc 2007; 129: 15398-404.
9. Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53: 323-32.
10. Johnson VA, Byington RE. Infectivity assay (virus yield assay). In: Aldovini A,Walker BD, eds. Techniques in HIV Research. New York: Stockton Press, 1990; 71-6.
11. Potts BJ. 'Mini' reverse transcriptase (RT) assay. In: Aldovini A,Walker BD, eds. Techniques in HIV Research. New York: Stockton Press, 1990; 103-6.
12. Lin PF, Blair W, Wang T et al.Asmall molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4receptor binding. ProcNatl Acad Sci USA 2003; 100: 11013-8.
13. Starcich BR, Hahn BH, Shaw G M et al. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 1986; 45: 637-48.
14. Zhou N, Nowicka-Sans B, Zhang S et al. In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043. Antimicrob Agents Chemother 2011; 55: 729-37.
15. Xiang SH, Kwong PD, Gupta R et al. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 2002; 76: 9888-9.
16. Schader SM, Colby-Germinario SP, Quashie PK et al. HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug. Antimicrob Agents Chemother 2012; 56: 4257-67.
17. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009; 77: 1655-64.
18. Moyle GJ, Wildfire A, Mandalia S et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191: 866-72.
19. Brower ET, Schon A, Freire E. Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors. Biochemistry 2010; 49: 2359-67.
20. Langley DR, Kimura SR, Sivaprakasam P et al. Homology models of the attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action. In: Abstracts of the Twentieth Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 2013. Abstract 542, p. 291. Foundation for Retrovirology and Human Health, Alexandria, VA,USA.
21. Kadow J, Langley D, Meanwell N et al. Protein-protein interaction targets to inhibit HIV-1 infection. In: Wendt M, ed. Topics in Medicinal Chemistry, vol. 8, Protein-Protein Interactions, Berlin: Springer, 2012; 105-66.
22. Da LT, Quan JM,Wu YD. Understanding the binding mode and function of BMS-488043 against HIV-1 viral entry. Proteins 2011; 79: 1810-9.
23. Kwong PD,Wyatt R, Robinson J et al. Structure of an HIVgp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648-59.
24. Kwon YD, Finzi A, Wu X et al. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci USA 2012; 109: 5663-8.